Interleukin 4 retards dissemination of a human B-cell lymphoma in severe combined immunodeficient mice

We have examined the antitumor activity of murine interleukin 4 (IL-4) on development of a human B-cell lymphoma (Daudi) in severe combined immunodeficient (SCID) mice. The progression of Daudi cells in SCID mice was followed by histological staining and by flow cytometric analysis of CD20+ cells in...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1995-09, Vol.55 (17), p.3692-3696
Main Authors: SCHWARZ, M. A, TARDELLI, L, MACOSKO, H. D, SULLIVAN, L. M, NARULA, S. K, FINE, J. S
Format: Article
Language:English
Subjects:
Animals
Antineoplastic agents
Biological and medical sciences
Drug Screening Assays, Antitumor
Humans
Immunity, Cellular
Immunotherapy
Interleukin-4 - administration & dosage
Interleukin-4 - adverse effects
Interleukin-4 - pharmacology
Kidney Neoplasms - pathology
Kidney Neoplasms - prevention & control
Lymphocytes - immunology
Lymphoma, B-Cell - immunology
Lymphoma, B-Cell - pathology
Lymphoma, B-Cell - prevention & control
Male
Medical sciences
Mice
Mice, SCID
Neoplasm Transplantation
Pharmacology. Drug treatments
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have examined the antitumor activity of murine interleukin 4 (IL-4) on development of a human B-cell lymphoma (Daudi) in severe combined immunodeficient (SCID) mice. The progression of Daudi cells in SCID mice was followed by histological staining and by flow cytometric analysis of CD20+ cells in spleen, liver, bone marrow, and kidneys. By day 35, CD20+ Daudi cells populate the majority of space in the bone marrow and kidney in vehicle-treated mice. Mice receiving i.p. injections of IL-4, commencing 7 or 14 days after tumor inoculation, exhibit a reduction in tumor burden as well as a decrease in CD20+ cells in both compartments. The antitumor activity of IL-4 does not appear to be due to an antiproliferative effect, since the cytokine does not alter the growth of Daudi cells in vitro, nor does it correlate with any marked cellular infiltrate in tumor-bearing tissues. In 51Cr-release assays, we observed that splenocytes from IL-4-treated mice were capable of lysing YAC-1 but not Daudi cell targets. Our findings demonstrate that: (a) systemic administration of IL-4 retards dissemination of a human B-cell lymphoma in SCID mice; and (b) antitumor activity elicited by IL-4 may not involve a direct effect on proliferation of Daudi cells or on the induction of cytolytic activity.
ISSN:0008-5472
1538-7445